VXLVaxil Bio Ltd.
0.2250CAD0.00%Mkt Cap: 896404 CADP/E: 1.25Last update: 2026-05-25
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vacc…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap896.40K CAD
Enterprise Value320.08K CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)522.00K CAD
Revenue/Share—
Last Price0.2250 CAD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)1.25
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.93
EPS (TTM)0.18
EPS (Forward)—
52W Range
0.130049% of range0.3250
52W High0.3250 CAD
52W Low0.1300 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE38.24%
ROA38.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-158.00K CAD
CapEx (TTM)—
FCF Margin—
FCF Yield-7.32%
Net Debt-447.00K CAD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio75.38
Quick Ratio57.38
Book Value/Sh0.2430 CAD
Cash/Share0.1630 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.98M
Float2.59M
Insiders5.61%
Institutions0.00%
Short Interest
Short Ratio0.4d
Short % Out.0.03%
Shares Short547
Short (prev mo.)6
Technical
SMA 500.2017 (+11.6%)
SMA 2000.1684 (+33.6%)
Beta-1.26
S&P 52W Chg28.31%
Avg Vol (30d)2.37K
Avg Vol (10d)71
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—